Oncology & Cancer

Promising drug combination for advanced prostate cancer

A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals ...

Medications

Abiraterone: Hint of considerable added benefit

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms ...

Oncology & Cancer

Abiraterone benefits chemo-naive with advanced prostate CA

(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study published online ...